Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiodesixBDSX -4.73%53 FCF Margin % is -6.76% as of Jun. 2026. GuruFocus rates BDSX with a GF Score™ of 53/100 and a GF Value™ of $21.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Biodesix ranks worse than 66.34% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biodesix's Free Cash Flow for the
three
months ended in Jun. 2026 was $-1.8 Mil. Biodesix's Revenue for the
three
months ended in Jun. 2026 was $26.9 Mil. Therefore, Biodesix's FCF Margin % for the quarter that ended in Jun. 2026 was -6.76%.
The historical data trend for Biodesix's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biodesix's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodesix FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biodesix's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodesix (BDSX) has a FCF Margin % of -6.76% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biodesix and its competitors. According to the industry distribution chart, Biodesix ranks #134 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 66.3%.
Is Biodesix's FCF Margin % too high?
Biodesix's current FCF Margin % is -6.76%. Based on the distribution chart, Biodesix ranks #134 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Biodesix has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's FCF Margin % compare to IMDX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Biodesix ranks #134 out of 202 companies for FCF Margin %. This places Biodesix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biodesix and its competitors. Biodesix's current FCF Margin % is -6.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Fairly Valued. The stock's GF Value™ is $21.33, compared to a current price of $22.34 — trading 4.7% above its estimated fair value. The current FCF Margin % is -6.76%. Biodesix's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biodesix (BDSX), the current FCF Margin % is -6.76% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodesix (BDSX) Overvalued in 2026?
Based on GuruFocus' analysis, Biodesix stock appears to be overvalued.
The current stock price of $22.34 is trading 4.7% above its estimated GF Value™ of $21.33.
GuruFocus considers Biodesix to be Fairly Valued.
Key valuation signals for BDSX:
FCF Margin %: -6.76%
GF Value™: $21.33 vs. price of $22.34 (4.7% above fair value)
No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
53GF Score
Get the complete analysis for BDSX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDSX has been successfully added to your 
